$ATRA News
Last published 1d ago
- 1d agoATRAAtara Biotherapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoATRAAtara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational ProgressBusiness WireTHOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2026 and business updates. “The resubmission of the tab-cel BLA was ...
- 4w agoATRAAtara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug AdministrationBusiness WirePrescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027 If Approved, Tab-cel Would Be the First Therapy Available in the U.S. for EBV+ PTLD Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in
- 1mo agoATRAAtara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug AdministrationBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 3mo agoATRAAtara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational ProgressBusiness WireProductive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87% Atara Biotherapeutics, Inc.
- 5mo agoATRAAtara Biotherapeutics Announces Changes to Its Board of DirectorsBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 5mo agoATRAANNUAL MEETING OF STOCKHOLDERS - ATARA BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning. I'm Enko Kokunoyan, and I am the President and Chief Executive Officer and a member of the Board of Atara Biotherapeutics. I am very happy to welcome you to the Atara Biotherapeutes' 2026 Annual Meeting of
- 5mo agoATRAANNUAL MEETING OF STOCKHOLDERS - ATARA BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning. I'm Enko Kokunoyan, and I am the President and Chief Executive Officer and a member of the Board of Atara Biotherapeutics. I am very happy to welcome you to the Atara Biotherapeutes' 2026 Annual Meeting of
- 5mo agoATRAThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of...
- 6mo agoATRAAtara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational ProgressBusiness WireProductive meeting held with the FDA; planning for tabelecleucel BLA resubmission Operating efficiencies and ATM proceeds extend cash runway into mid-2027 Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in
- 6mo agoATRAThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of...
- 6mo agoATRAAtara Biotherapeutics Provides Regulatory Update on TabelecleucelBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 6mo agoATRAThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of...
- 7mo agoATRAATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff RoleGlobeNewswireNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA) investment, contact Lauren Molinaro of Kirby McInerney LLP by email
- 8mo agoATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational ProgressBusiness WireAtara delivers significant operational efficiencies and extends cash runway through year-end 2026 A Type A meeting has been scheduled between Pierre Fabre Pharmaceuticals and the FDA Atara Biotherapeutics, Inc.
- 8mo agoATRAAtara Biotherapeutics Provides Regulatory Update on TabelecleucelBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 8mo agoATRAAtara Biotherapeutics Provides Regulatory Update on TabelecleucelBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 8mo agoATRAAtara Biotherapeutics Provides a Business UpdateBusiness WireAtara renegotiates one-time milestone payment with HCRx Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop
- 10mo agoATRAPIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATIONPR NewswireOn January 9, 2026, Pierre Fabre Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...
- 10mo agoATRAAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)Business WireU.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV)
- 12mo agoATRAAtara Biotherapeutics Announces Third Quarter Financial Results and Operational ProgressBusiness WireTab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has completed the transfer of substantially all tab-cel activities, including BLA sponsorship, and associated costs to Pierre
- 1y agoATRAPierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)PR NewswirePierre Fabre Pharmaceuticals Inc. (PFP) announces the transfer of the Biologics License Application (BLA) for tabelecleucel from Atara...
- 1y agoATRAAtara Biotherapeutics Announces Changes to Its Board of DirectorsBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 1y agoATRAAtara Biotherapeutics Announces Second Quarter Financial Results and Operational ProgressBusiness WireTab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has transferred substantially all operational activities and associated costs related to tab-cel to Pierre Fabre
- 1y agoATRAPierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)PR NewswirePierre Fabre Pharmaceuticals Inc. (PFP) announces the acceptance by U.S. Food and Drug Administration (FDA) of the Biologics License Application...
- 1y agoATRAAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative DiseaseBusiness WirePrescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell
- 1y agoATRAPerre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.PR NewswirePierre Fabre Pharmaceuticals, Inc. today announced the transfer of the Investigational New Drug Application for tabelecleucel from its partner, Atara ...
- 1y agoATRAAtara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)Business WireAtara Biotherapeutics Resubmits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease to the U.S. FDA Approval of BLA
- 1y agoATRACDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager PlatformBusiness WireExperienced, strategic biopharma leader with 40 years of global biopharma experience CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of
- 1y agoATRAAtara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of DirectorsBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 1y agoATRAAtara Biotherapeutics Announces First Quarter Financial Results and Operational ProgressBusiness WireAtara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization
- 1y agoATRAAtara Biotherapeutics Announces Pricing of $16 Million OfferingBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 1y agoATRAAtara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)Business WireFDA lifts clinical hold enabling resumption of clinical trials FDA has granted a Type A Meeting to discuss path forward for BLA Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging
- 1y agoATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational ProgressBusiness WireAtara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value of EBVALLO and has
- 1y agoATRAAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 1y agoATRAWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities lawsGlobeNewswirePLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights
- 1y agoATRAWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities lawsGlobeNewswirePLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights
- 1y agoATRAAtara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219Business WireU.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy,
- 1y agoATRAAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)Business WireAtara received FDA Complete Response Letter (CRL) solely related to inspection findings at third-party manufacturer CRL did not identify deficiencies related to clinical efficacy or safety data in the Biologics
- 1y agoATRAAtara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx ConferenceBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 1y agoATRAAtara Biotherapeutics to Participate at the Stifel 2024 Healthcare ConferenceBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 1y agoATRAAtara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational ProgressBusiness WireTab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025 First Patient Dosed for ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected Q1 2025 ATA3219 Lupus Nephritis and
- 2y agoATRAAtara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024Business WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 2y agoATRAAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 2y agoATRAAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 2y agoATRAAtara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 2y agoATRAAtara Biotherapeutics Announces $36 Million Registered Direct OfferingBusiness WireLed by Existing Top Institutional Investors With Participation From a New Strategic Investor Well Positioned To Execute on Tab-cel® U.S. BLA Approval and Advancement of ATA3219 Further Strengthens Balance Sheet
- 2y agoATRAAtara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership UpdateBusiness WireTab-cel® U.S. BLA Accepted Under Priority Review With PDUFA Action Date of January 15, 2025 ATA3219 Lupus Nephritis and Severe Systemic Lupus Erythematosus Study Initiation Expected Q4 2024; Initial Clinical Data
- 2y agoATRAAtara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceBusiness WireAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
- 2y agoATRAAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative DiseaseBusiness WirePrescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from